methotrexate + vinblastine + doxorubicin + cisplatin + pegfilgrastim

This is a multi-agent chemotherapy regimen composed of five drugs: - **Methotrexate** is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication. - **Vinblastine** is a vinca alkaloid that disrupts microtubule formation, inhibiting mitosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, preventing replication and transcription. - **Pegfilgrastim** is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) analog used to stimulate neutrophil production and reduce the risk of infection during myelosuppressive chemotherapy[6][7][8]. This combination does not have a unique brand or code name but represents the concurrent use of these agents. The regimen may be used in various cancer settings where aggressive cytotoxic therapy with supportive care for neutropenia (via pegfilgrastim) is indicated.